ASH 2018 | MRD highlights in myeloma from ASH 2018
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, NY, gives his insight into the measurable residual disease (MRD) data from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up